HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MRNA

Moderna, Inc. (Nasdaq 100, S&P 500)

Healthcare — Biotechnology

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Hold 2.9 / 5 19 analysts
$55.81
+$0.17 (+0.31%)
Target: $49.37 (-11.5%)
Sign in to add MRNA to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$22.14B
P/E Ratio (TTM)-
Forward P/E-13.30
EPS (TTM)$-8.14
Dividend Yield-
Profit Margin-143.55%
Revenue Growth260.20%
ROE-36.56%
Debt/Equity17.52
Recommendation Hold 2.9
Analyst Target$49.37
Analysts19
Indexes Nasdaq 100 S&P 500

Technical Indicators

RSI (14)19.9
Beta0.94
SMA 20$66.50
SMA 40$60.53
52-Week High$85.60
52-Week Low$22.28
50-Day Avg$57.80
200-Day Avg$44.29
Avg Volume$7.78M
Volume$5.55M

Performance Analysis

NEUTRAL

MRNA presents a mixed picture with both positive and negative indicators.

~ Trading at 53% of its 52-week range.
+ RSI at 19.9 signals oversold conditions — a bounce may be ahead.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+ Strong revenue growth of 260.2% year-over-year.
- Operating at a loss with -143.6% margin.
~ Wall Street consensus is "Hold" from 19 analysts.
- Average analyst target of $49.37 implies 11.5% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report